Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
6.325 USD | +0.88% | -0.55% | -27.88% |
Mar. 27 | MiMedx Group Says FDA Affirms Axiofill Falls Short of Regulatory Standards for Tissue-Based Products | MT |
Mar. 27 | MiMedx Says FDA Still Won't Budge on Axiofill Designation, Files Lawsuit | DJ |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.88% | 925M | |
-20.60% | 128M | |
-16.90% | 67.46M | |
+6.64% | 60.58M | |
+0.60% | 51.45M |
- Stock Market
- Equities
- MDXG Stock
- News MiMedx Group, Inc.
- HC Wainwright Adjusts Price Target on Medx Group to $8 From $9.50, Keeps Buy Rating